Compare AbCellera Biologics Inc (ABCL) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs McCormick & Company, Incorporated — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while McCormick & Company, Incorporated trades at $51.84 (market cap $14.04B). The key difference: McCormick & Company, Incorporated is far larger — about 6× AbCellera Biologics Inc's market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MKC | |
|---|---|---|
Market Cap | $2.35B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $72.90 |
52-Week Low | $2.78 | $45.60 |
Enterprise Value | $1.99B | $18.64B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
McCormick (MKC) trades at $52.22, down 2.3% today but maintains a bullish technical outlook with strong support at $51. The company delivered solid Q2 2026 results with earnings of $0.80 per share beating estimates, driven by 14% constant currency sales growth and margin expansion to 40.2%. Valuation metrics appear attractive with a P/E of 8.62 and P/S of 1.89, while analyst consensus targets $59.67 representing 14% upside potential.
The investment case centers on MKC's defensive positioning in consumer staples, transformative Unilever food business combination potential, and improving profitability. Key risks include soft consumer volume trends in the Americas and execution challenges from the pending acquisition. With 36.7% of analysts rating the stock a buy and institutional ownership stable, MKC offers value with a 4% dividend yield amid ongoing operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
